Caregivers Day

In English
Caregivers Day, as part of ISFTD2024, will be held for family members and professional caregivers on Saturday, 21 September, 2024.

The registration fee for attending Caregivers Day only is EUR 50.

A full congress registration is required if you are also planning to attend the ISFTD 2024 congress on the other days. During registration for the congress, you can indicate that you will be attending the Caregivers Day. Click here for registration for ISFTD 2024.

 

In het Nederlands
Caregivers Day, als onderdeel van ISFTD2024, wordt gehouden voor familieleden en professionele zorgverleners op zaterdag 21 september 2024.

Het inschrijfgeld voor het bijwonen van alleen Caregivers Day is EUR 50.

Een volledige congresregistratie is vereist als u ook van plan bent het ISFTD 2024 congres op de andere dagen bij te wonen. Tijdens de registratie voor het congres kunt u aangeven dat u Caregivers Day bijwoont. Klik hier voor registratie voor ISFTD 2024.

 

Programme overview

In English
Dutch/English translation will be offered for the sessions in the morning and for parallel session 3 in the afternoon.
Parallel sessions 1 + 2 in the afternoon will only be offered in Dutch.

 

In het Nederlands
Nederlands/Engelse vertaling zal worden aangeboden voor de ochtendsessies en voor parallelsessie 3 in de middag. Parallelsessies 1 en 2 in de middag zullen alleen in het Nederlands worden aangeboden.

Gerjoke

Time: 16:20 - 16:40 CET

Connections for Care: Community Advocacy and Support at Every Stage of Life with FTD

Time: 15:00 - 15:35 CET

Verbindingen voor zorg: Belangenbehartiging en ondersteuning van de gemeenschap in elke fase van het leven met FTD

Biopharma perspective

Time: 17:10 - 17:20 CET

O10.7: TBD

Time: 15:00 - 15:15 CET

O10.5: TBD

Time: 14:45 - 15:00 CET

O10.5: TBD

Time: 14:30 - 14:45 CET

O10.4: TBD

Time: 14:15 - 14:30 CET

O10.3: TBD

Time: 14:00 - 14:15 CET

O10.2: TBD

Time: 13:45 - 14:00 CET

Discussion – tools and resources to enable clinical trials

Time: 17:30 - 18:00 CET

Non-profit perspective, including the dearth of available participants for active trials, and high-level of known barriers

Time: 17:20 - 17:30 CET

O03.4: Optimizing recruitment for clinical trials in FTD, introduction to panel discussion

Time: 17:00 - 17:10 CET

O03.3: An international COS-PPA; a consensus study to identify a core outcome set for PPA

Time: 16:50 - 17:00 CET

O03.2: The Multidomain impairment rating (MIR) Scale: Comparison to the CDR+NACC FTLD in the ALLFTD consortium

Time: 16:40 - 16:50 CET

O03.1: Platform trials for FTD and PSP

Time: 16:30 - 16:40 CET

Q&A session 01.2 Diversity & Epidemiology

Time: 12:45 - 12:50 CET

Q&A session 01.1: Diversity & Epidemiology

Time: 11:42 - 11:45 CET

test

Time: 00:00 - 00:00 CET

Opening

Time: 09:30 - 10:00 CET

Opening

TBA

Time: 15:40 - 16:20 CET

Volgt

TBA

Time: 13:30 - 13:50 CET

Volgt

TBA

Time: 14:10 - 14:40 CET

Volgt

PB7.5: Practice effects are reduced within prodromal and symptomatic FTD mutation carriers using the Ignite app

Time: 11:16 - 11:20 CET

PB7.2: Transcranial Direct Current Stimulation for Primary Progressive Aphasia: Individualised Targeting Using Neuroimaging

Time: 11:04 - 11:08 CET

PB7.4: The dynamics of auditory working memory impairment in primary progressive aphasia and Alzheimer’s disease

Time: 11:12 - 11:16 CET

PB7.3: Spontaneous speech alterations and evolution in primary progressive aphasia variants 

Time: 11:08 - 11:12 CET

PB7.1: The Empathy Effect: Improving FTD Support, Medical Practices and Societal Awareness with an Immersive Approach

Time: 11:00 - 11:04 CET

O13.8: TBD

Time: 10:15 - 10:30 CET

O13.7: Glymphatic dysfunction occurs across clinical phenotypes of motor neuron disease

Time: 10:00 - 10:15 CET

O13.6: Effects of blood-brain barrier opening with ultrasounds combined to microbubbles on tau prion-like propagation

Time: 09:45 - 10:00 CET

O13.5: Blood-based inflammation markers relate to neuroinflammation and survival in syndromes associated with frontotemporal lobar degeneration

Time: 09:30 - 09:45 CET

O13.4: Ultra-high resolution T2*-weighted ex vivo 7T MRI laminar patterns of pathology in FTLD

Time: 09:15 - 09:30 CET

O13.3: Carboxy-terminal blockade of sortilin binding enhances progranulin gene therapy, a potential treatment for FTD

Time: 09:00 - 09:15 CET

O13.2: New insights into aFTLD-U through the brain transcriptomics analysis

Time: 08:45 - 09:00 CET

O13.1: Discovery of Novel Splicing Alterations in FTLD-TDP: Insights from Brain transcriptomics Using Short-and Long-read sequencing

Time: 08:30 - 08:45 CET

O06.5: RNA-binding protein misloclization in FTLD and ALS

Time: 12:45 - 13:00 CET

O06.4: Neuroinflammation and protein aggregation and its relationship to cognitive decline in FTD

Time: 12:30 - 12:45 CET

O.06.3: Cryptic RNA/proteins as a reporter of TDP-43 pathology in neurodegenerative diseases 

Time: 12:15 - 12:30 CET

O06.2: Neuropathology-based approaches reveal novel pathogenic aspects of progressive supranuclear palsy

Time: 12:00 - 12:15 CET

O06.1: Annexin A11 proteinopathy in ANXA11 variant cases and FTLD-TDP Type C

Time: 11:45 - 12:00 CET

O10.1: TBD

Time: 13:30 - 13:45 CET

PB4.4: White matter Hyperintensities are an early biomarker in GRN-related FTD

Time: 11:57 - 12:00 CET

PB4.3: Genetic influences on progression of clinical, motor, fluid biomarker and MRI changes in familial FTLD

Time: 11:53 - 11:57 CET

PB4.2: UNC13A polymorphism shortens survival in behavioural variant frontotemporal dementia

Time: 11:49 - 11:53 CET

PB4.1: Integrative transcriptomic analysis of the frontal cortex reveals an upregulation of S100A6 in FTLD-TDP

Time: 11:45 - 11:49 CET

O09.6: TMEM106B loss-of-function impairs the presynaptic protein machinery in human iPSC-derived cortical neurons

Time: 11:30 - 11:45 CET

O09.5: C9orf72 repeat expansion affects immune response in a xenografted microglia mouse model

Time: 11:15 - 11:30 CET

O09.4: AlphaFold2 Modeling of MAPT mutation-derived Tau conformations Plus biochemical data support TauC3’s involvement in FTLD-Tau

Time: 11:00 - 11:15 CET

O09.3: TDP-43 monomerization drives early pathological changes in FTD 

Time: 10:00 - 10:15 CET

O09.2: Regulation of tau phosphorylation, secretion and splicing by variations in temperature during the sleep-wake cycle

Time: 09:45 - 10:00 CET

Cross links between FTD and MND

Time: 18:15 - 18:45 CET

The history of FTD

Time: 10:30 - 11:00 CET

O09.1: Synaptic dysfunction in FTD patient-derived iPSC-neurons

Time: 09:30 - 09:45 CET

O08.5: Unbiased CSF proteomics reveals genotype-specific signatures of presymptomatic and symptomatic familial frontotemporal lobar degeneration

Time: 18:15 - 18:30 CET

O08.4: Early dysregulation of microglia-secreted AIM in frontotemporal dementia caused by CHMP2B mutation

Time: 18:15 - 18:30 CET

O08.3: CSF TMEM106B as a fluid biomarker in familial and sporadic frontotemporal lobar degeneration

Time: 18:00 - 18:15 CET

O08.2: Clinical Performance of Plasma Aβ1-42/Aβ1-40, p-tau217 and Neurofilament Light in Sporadic Frontotemporal Dementia Spectrum Disorders

Time: 17:45 - 18:00 CET

O08.1: Detection of TDP-43 seeding activity in the olfactory mucosa from patients with Frontotemporal Dementia

Time: 17:30 - 17:45 CET

PB3.4: Psychoeducational program in Primary Progressive Aphasia: An innovative collaboration between the community and academic environments

Time: 15:57 - 16:31 CET

PB3.3: The Position of Sporadic FTD Cases within the Human Proteomics Neurodegenerative Disease Landscape

Time: 15:53 - 15:57 CET

PB3.2: The identification of GRN mutation carriers by a simple finger stick collection – DropAD

Time: 15:49 - 15:53 CET

PB3.1: CSF/serum albumin ratio in frontotemporal lobar degeneration syndromes

Time: 15:45 - 15:49 CET

O07.5: Memory in behavioural-variant frontotemporal dementia: comparison with normative data and amnestic and non-amnestic Alzheimer’s disease

Time: 15:30 - 15:45 CET

O07.4: The Mini-Linguistic State Examination as new screening tool for primary progressive aphasia: development and validation of the Dutch/Flemish version

Time: 15:15 - 15:30 CET

O07.3: Criminal minds in dementia: A systematic review & quantitative meta-analysis

Time: 15:00 - 15:15 CET

O07.2: The Signature Initiative 2 years later: towards the clinical recommendations for socio-cognitive assessment in neurocognitive disorders

Time: 14:45 - 15:00 CET

O07.1: Exploring Emotion and emotional variability as digital biomarkers in Frontotemporal dementia speech

Time: 14:30 - 14:45 CET

PB6.4: Detection of misfolded TDP-43 in CSF from genetic FTD and FTD/ALS patients

Time: 17:38 - 17:42 CET

PB6.3: Progranulin deficiency in microglia and its impact in neurodegeneration

Time: 17:34 - 17:38 CET

PB6.2: Increased levels of TMEM106B lead to lysosomal dysfunction and aberrant neurotrophin signaling in mice

Time: 17:34 - 17:38 CET

PB6.1: Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes

Time: 17:30 - 17:34 CET

O12.2: Utility of case review meetings in Japanese FTD consortium FTLD-J

Time: 17:15 - 17:30 CET

O12.1: Towards improved knowledge of the phenotypes associated with C9orf72 repeat expansion – A multicenter cohort study

Time: 17:00 - 17:15 CET

PB5.4: Behavioural variant frontotemporal dementia and Alzheimer’s disease differ in favourite music activation profiles on fMRI

Time: 16:57 - 17:00 CET

PB5.3: Neuropsychiatric shadows: Unraveling the deeper ties of psychotic symptoms in bvFTD

Time: 16:53 - 16:57 CET

PB5.2: Paying attention – what hallucinations reveal about FTD

Time: 16:49 - 16:53 CET

PB5.1: Connectomic markers of executive function in FTLD and typical aging

Time: 16:45 - 16:49 CET

O11.2: Differential diagnosis of motor speech disorders in FTD; a case-based tutorial

Time: 16:30 - 16:45 CET

O11.1: Longitudinal behavioral and neuropsychiatric changes in genetic frontotemporal dementia: from presymptomatic to symptomatic conversion

Time: 16:15 - 16:30 CET

PB2.4: Onset-predictive biomarker testing for clinical trial recruitment in FTD: perspectives of (potential) mutation carriers

Time: 09:42 - 09:45 CET

PB2.3: Interim Safety and Biomarker Data From upliFT-D Trial of PBFT02 in FTD with GRN Mutations

Time: 09:38 - 09:42 CET

PB2.2: Communication Bridge 2: Results from a global randomized controlled trial (RCT) for primary progressive aphasia

Time: 09:34 - 09:38 CET

PB2.1: Baseline characteristics for INFRONT-3: A Phase 3 double-blind, placebo-controlled 96-week study evaluating latozinemab in FTD-GRN

Time: 09:30 - 09:34 CET

O05.2: Differentiating sporadic bvFTD from late-onset PPD: the DIPPA-FTD study

Time: 09:15 - 09:30 CET

O05.1: Disentangling Behavioral Problems in Dementia Subtypes: From Fixed Interests to Empathy Deficits

Time: 09:00 - 09:15 CET

PB1.4: The influence of cultural background on social cognition in genetic FTD

Time: 12:35 - 12:45 CET

O04.4: Deciphering Distinct Genetic Risk factors for FTLD-TDP subtypes via whole genome sequencing

Time: 18:45 - 19:00 CET

O04.3: Investigation of genetic modifiers in the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Study

Time: 18:30 - 18:45 CET

O04.2: Understanding the role of somatic mutations in TARDBP in FTLD-TDP type C

Time: 18:15 - 18:30 CET

O01.8: Sex differences in clinical phenotypes of behavioural variant frontotemporal dementia

Time: 12:25 - 12:35 CET

O01.7: Influence of Biological Sex on Cognitive Resilience in Genetic FTLD

Time: 12:15 - 12:25 CET

O01.6: Frontotemporal Dementia in India – Perspective and unique insights

Time: 12:05 - 12:15 CET

O01.5: Predictors of survival in syndromes associated with Frontotemporal Lobar Degeneration: a European registry

Time: 11:55 - 12:05 CET

O01.4: Neurodevelopmental trajectories towards neurodegenerative disease

Time: 11:45 - 11:55 CET

PB1.3: Insights into Dyslexia Phenotypes and Hypometabolism in Spanish-Speaking Patients with Primary Progressive Aphasia

Time: 11:38 - 11:45 CET

PB1.2: Bilingualism contributes to resilience in AD but not FTLD syndromes

Time: 11:34 - 11:38 CET

PB1.1: Cross-Linguistic Assessment Of Oral Production In Primary Progressive Aphasia: Insight From English, Chinese, and Italian

Time: 11:30 - 11:34 CET

O01.3: Navigating dysgraphia phenotypes in Chinese lvPPA: A clinical and imaging analysis

Time: 11:20 - 11:30 CET

O02.5: Individualized atrophy-based prediction of dementia progression in familial FTLD with Bayesian LME modeling

Time: 15:00 - 15:15 CET

O02.4: Validating 11C-PK11195 PET in pathologically heterogeneous FTD

Time: 14:45 - 15:00 CET

O02.3: Altered spatiotemporal dynamics of interoception associated with social cognition impairment in bvFTD

Time: 14:30 - 14:45 CET

O02.2 – Mapping the staging of neuroimaging trajectories in FTD: new insights using voxel-based analysis

Time: 14:15 - 14:30 CET

Session 04 – Genetics

Time: 17:30 - 18:30 CET

Session 03 – Clinical trials and Management

Time: 16:00 - 17:30 CET

O02.1: Uncovering distinct trajectories of brain atrophy and tau deposition in PSP

Time: 14:00 - 14:15 CET

O01.2: Brain imaging profiles of apraxia of speech and agrammatism in Japanese and English speakers diagnosed with nonfluent variant primary progressive aphasia

Time: 11:10 - 11:20 CET

O01.1: A cross-linguistic review of the quantitative markers of speech and language of the FTD Spectrum

Time: 11:00 - 11:10 CET

O04.1: Multi-transcriptomic analyses reveal altered expression profiles in Pick’s disease parietal tissue

Time: 18:00 - 18:15 CET

Panel discussion

Time: 16:00 - 17:30 CET

Clinical trials and management / Trial design

Closing with drinks

Time: 16:40 - 17:30 CET

Afsluiting met drankje

Palliative care

Time: 15:40 - 16:20 CET

Palliatieve zorg

Management of behavioural symptoms

Time: 15:40 - 16:15 CET

Omgaan met probleemgedrag

Management of mourning

Time: 15:00 - 15:35 CET

Omgaan met levende rouw

Language variants

Time: 15:00 - 15:35 CET

Taalvarianten

Break

Time: 14:40 - 15:00 CET

Pauze

Legal aspects

Time: 14:10 - 14:40 CET

Juridische aspecten

Music therapy

Time: 14:10 - 14:40 CET

Muziek therapie

Management of behavioural symptoms

Time: 13:30 - 13:50 CET

Omgaan met probleemgedrag

Genetic FTD

Time: 13:30 - 13:50 CET

Erfelijke FTD

Information national young onset dementia cohort

Time: 12:20 - 12:35 CET

Informatie landelijk dementie op jonge leeftijd cohort

Poster sessions

Time: 12:35 - 13:30 CET

Poster sessies

LUNCH with info stands

Time: 12:35 - 13:30 CET

LUNCH met info stands

Interview with caregiver

Time: 12:00 - 12:20 CET

Interview met naaste

From a caregiver perspective

Time: 11:20 - 11:40 CET

FTD vanuit mantelzorg perspectief

Break

Time: 11:30 - 12:00 CET

Pauze

Therapeutic developments and medication trials

Time: 10:30 - 10:50 CET

Therapeutische ontwikkelingen en medicijn trials

Challenges in non-genetic FTD

Time: 10:50 - 11:10 CET

Uitdagingen bij niet erfelijke FTD (diagnose)

FTD and related disorders: an overview and recent developments

Time: 10:00 - 10:30 CET

FTD en gerelateerde ziekten: een overzicht en recente ontwikkelingen

Welcome, registration, coffee

Time: 09:00 - 09:30 CET

Inloop – inschrijven – koffie

Clinical Case discussion

Time: 09:00 - 09:45 CET

Closing ceremony

Time: 12:30 - 13:00 CET

Oral presentations

Time: 11:15 - 12:30 CET

consortia presentation

Speech of the President of the ISFTD

Time: 13:45 - 14:00 CET

Presentation of the next venue (ISFTD2026)

Time: 13:30 - 13:45 CET

Panel discussion

Time: 16:00 - 16:00 CET

Communication on FTD: how to deal with the stigma and how to generate awareness

Plenary session

Time: 13:30 - 14:00 CET

Cross cultural aspects of cognition in FTD

Opening act

Time: 10:00 - 10:30 CET

Plenary session

Time: 11:00 - 11:30 CET

Gala dinner

Time: 19:00 - 23:00 CET

Speech of the President of the ISFTD

Time: 18:10 - 18:10 CET

Presentation of the next venue

Time: 18:10 - 18:10 CET

Opening & Welcome reception

Time: 19:30 - 21:00 CET

Poster Blitz sessions

Time: 11:00 - 11:15 CET

Poster Blitz sessions

Time: 11:30 - 11:45 CET

Poster Blitz sessions

Time: 11:30 - 11:45 CET

Poster Blitz sessions

Time: 12:15 - 12:30 CET

Oral presentations

Time: 08:30 - 10:30 CET

Oral presentations

Time: 17:15 - 18:30 CET

Oral presentations

Time: 14:00 - 16:00 CET

Oral presentations

Time: 08:30 - 10:30 CET

Oral presentations

Time: 17:00 - 18:45 CET

Oral presentations

Time: 14:00 - 15:30 CET

Oral presentations

Time: 09:45 - 11:00 CET

Break

Time: 16:00 - 16:45 CET

Break

Time: 10:30 - 11:00 CET

Break

Time: 10:30 - 11:00 CET

Break

Time: 15:30 - 16:00 CET

Break

Time: 11:00 - 11:30 CET

FTD in a dish / New models in FTD

Time: 16:00 - 16:30 CET

Oral presentations

Time: 13:45 - 15:00 CET

Oral presentations

Time: 17:30 - 18:30 CET

Oral presentations

Time: 11:00 - 12:15 CET

FTD from bench to bedside

Time: 08:00 - 08:30 CET

Plenary session

Time: 16:45 - 17:15 CET

FTLD pathology and copathology

TDP pathophysiology

Time: 08:00 - 08:30 CET

Plenary session

Time: 18:10 - 18:10 CET

A functional network approach to FTD

Time: 08:00 - 08:30 CET

Lunch

Time: 13:00 - 14:00 CET

Lunch break, Poster viewing, visiting exhibition

Time: 11:45 - 13:30 CET

Lunch break, Poster viewing, visiting exhibition

Time: 11:45 - 13:30 CET

Lunch break, Poster viewing, visiting exhibition

Time: 12:30 - 13:30 CET

Plenary session

Time: 10:30 - 11:00 CET

The history of FTD

Break

Time: 15:00 - 15:30 CET

Registration open

Time: 08:30 - 10:00 CET